All In Biotech

Drug Trial Radar · NCT06450106

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

A Phase 1 Dose Escalation Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

May 8, 2025

Primary completion

Sep 2026

Study completion Dec 2026

Sponsor

Lead sponsor
SURGE TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

Conditions

  • Prostate Cancer

Interventions

  • STM-416pDrug

    STM-416p monotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability]Time frame: 21 Days
  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Time on trial up to 90 days

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Arizona Urology Specialists

    Tucson, Arizona · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Australian Prostate Center

    Melbourne N., Victoria, Australia · Recruiting

  • Epworth HealthCare

    Melbourne N., Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.